The National Institutes of Health is changing its standard application dates for SBIRs/STTRs to speed up the disbursal of funds to successful applicants. The current deadlines are April 5, August 5, and December 5. Beginning in September 2015, the new dates will be September 5, January 5, and April 5. Essentially, this means that the next two deadlines for this mechanism are April 5, 2015, and September 5, 2015, with the August 5 deadline being eliminated. Read the whole notice here.
The National Institutes of Health has updated and simplified its policy on submitting late applications, beginning with applications due January 25, 2015 or later. They have added a two week window after the due date during which a request to accept a late application may be considered, and they have eliminated the previous practice of assigning different late application windows to different funding mechanisms, or in some cases, not allowing them at all. Now, all applications will have the same two-week window. Note that the reasons for accepting a late application include things like a death in the family, severe illness, natural disasters, or adhoc service to NIH in the two months before or after the deadline. Lots of teaching or administrative duties, failure to follow instructions, or your hard drive dying–not so much. Read the full policy here.
Like most academic scientists, Mark Slifka wears many hats – principle investigator, grant writer, manuscript editor, manager, and administrator, to name a few. Perhaps less common is his entrepreneurial “hat.” Dr. Slifka is the president and Chief Scientific Officer (CSO) of Najít Technologies, Inc., a clinical stage startup company based on a platform vaccine technology that he developed at OHSU’s West Campus.
Najít’s platform uses a novel, patented approach to inactivate viruses while still maintaining their key immunogenic structures. This technology is unique in comparison to other vaccine technologies because the inactivation method employed uses oxidation instead of alkylation or cross-linking by formaldehyde. The oxidation method is simple, safe, and more immunogenic than other more outdated vaccine approaches.
- Simplicity in process means that the platform will be easier to get through the appropriate regulatory processes.
- This technology is safer for clinical development, since it uses inactivated viruses instead of live viruses.
- The vaccines produced are more immunogenic, meaning that the vaccine is better recognized by the immune system, which triggers an improved immune response.
Najít’s pipeline currently includes vaccines for Yellow Fever, West Nile, and Dengue viruses, which have SBIR, U01, and R01 funding to perform clinical-grade manufacturing in addition to an NIH contract to perform a Phase I clinical trial of their current West Nile virus vaccine. Part of Najit’s success is due to how the company chooses its pipeline. Some factors considered are:
OHSU’s Office of Proposal and Award Management (OPAM) will be closed the following days: Dec. 24, 26 and 31, and Jan. 2. If you need an emergency signature/grant submission, please contact the following individuals:
Friends of Doernbecher, a volunteer organization that raises funds for Doernbecher Children’s Hospital at OHSU, seeks proposals for pediatric-related research projects and programs. The grant program, which provides up to $175,000, is open to any employee of OHSU or Doernbecher proposing research related to children’s health. This includes, but is not limited to, OHSU and Doernbecher faculty, clinical and research staff, graduate students, medical students, fellows, and postdoctoral fellows. Grant applications are due February 6, 2015.
The Vollum Writing Class is a 6-week professional science writing course open to OHSU graduate students, postdoctoral fellows, and junior faculty.
This class uses short lectures, class discussion, and workshop-style writing assignments to help researchers learn to write better papers and grants. Topics include:
- The basic elements of good scientific writing style, including sentence and document structure
- Insight into scientific conventions regarding grammar, punctuation, and usage;
- Strategies for revising
- Dealing with writer’s block and time management
- Best practices for writing introductions, results, discussions, and grant proposals
The class runs for six weeks, 9:30 a.m. to 12 p.m. on Wednesdays, beginning Jan. 7, 2015. Six individual tutorials with the instructor are included. There are no prerequisites for this non-credit professional development course, but you should not take the class unless you have enough data to write about.
The course carries a fee of $500 per student (unless you are in a Vollum lab or part of certain graduate Ph.D. programs). Questions? Contact firstname.lastname@example.org.
Are you ready or interested in joining the next league of biomedical inventors and entrepreneurs? If so, please join us for INVENT, an educational program on bioscience innovation and entrepreneurship. Two keynote presentations and a series of weekly seminars will provide information on translating and commercializing discoveries in the health and life sciences. Attendance is free, and medical students, grad students, post-doc fellows, faculty, and members of the bioscience community are all encouraged to attend. Medical students who attend all seminars in a series could qualify for course credit. Please visit the Biomedical Innovation Program for details and registration information.
INVENT: Keynote and Seminar Series, Winter 2015
- When: Every Wednesday from Jan. 7, 2015 through Mar. 11, 2015 – 5 to 6:30 p.m.
- Where: OHSU Collaborative Life Sciences Building (CLSB), South Waterfront, Room 3A001
Jan. 7: OHSU’s Drs. Albert Starr, Richard Wampler, and Kent Thornburg: “First the Valve, then the Heart – How Logic is Not Essential to Innovation”
Mar. 11: Michael Baker, The Baker Group: “From Sketch to Launch – The Pathway to Commercialization of Innovations”
- Translation and the entrepreneurial mindset
- Evaluating your concept
- Protecting your concept
- Testing your concept
- Pitching your concept
- Seeking funds
- Building collaborations
- Projecting yourself and others
- Operating responsibly ethically
- Building the business model and plan
This educational series is truly a collaborative event and is brought to you, in part, by the Oregon Clinical & Translational Research Institute, the School of Medicine, Knight Cardiovascular Institute, the Division of Management and Technology Transfer & Business Development.
More news from OPAM: The new Subrecipient Commitment Form is complete and can be found on the Research Development & Administration Forms Page, with accompanying guidance. As discussed at several RAIN presentations, this new form will replace the Letter of Intent currently required for grant proposal submissions that include outgoing subaward agreements. Currently, most other institutions are using a version of this form; it is considered an industry standard and is expected by many sponsors and subrecipients at the proposal stage.
Why change now? Although OPAM was looking to use a form aligned with current industry standards in the not-so-distant future, the change is occurring now to align with changes in federal regulations (specifically, Uniform Guidance) requiring this information at time of submission. The Subrecipient Commitment Form will be required for all (including non-Federal) grant submissions and outgoing subaward requests as of February 5th, 2015.
This just in from the OHSU Office of Proposal and Award Management: effective Monday, December 15th, if a proposal includes key personnel from a different department with at least 5% effort, it can be routed as Information Only to the key person, their department chair or unit head, and their dean or director.
This is a significant change to the previous requirement to route the proposal for Approval. The Information Only route will notify individuals listed but will not delay the rest of the approval route.
Approval by the PI, the department chair and the dean or director is still required.
Please note that if you have answered Yes to the ePPQ question regarding the use of Non-Human Primates, ONPRC approval is required.
The InfoEd Electronic Routing User Guide has been updated and has instructions on adding an Information Only individual to the route.
An international group of more than 200 scientists–including Oregon Health & Science University neuroscientist Claudio Mello, Ph.D.–has released the genome of common birds for the first time. This work illuminates the evolution of birds, including details about how they developed song.
The consortium is publishing 23 papers across multiple journals this week, including 8 papers in a Dec. 12 special issue of Science. The 48 bird species studied include the crow, duck, and eagle, as well as Anna’s hummingbird, which is common in the Pacific Northwest and the subject of Mello’s work.
Mello is an international expert on learning and memory, in particular how birds learn to vocalize. He is a co-author of three of the Science articles and the senior author on two other papers. The Mello lab has also been involved in cataloguing the brain expression of a large collection of genes in songbirds, an online atlas that played a fundamental role in the comparative studies of the consortium. Read the full story here.